Shopping Cart
- Remove All
Your shopping cart is currently empty
Icotinib Hydrochloride (BPI-2009H) is the hydrochloride salt form of icotinib, an orally available quinazoline-based inhibitor of EGFR, with potential antineoplastic activity. Icotinib selectively inhibits the wild-type and several mutated forms of EGFR tyrosine kinase. This may lead to an inhibition of EGFR-mediated signal transduction and may inhibit cancer cell proliferation. EGFR, a receptor tyrosine kinase, has been upregulated in a variety of cancer cell types.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 5 mg | $55 | In Stock | |
| 10 mg | $80 | In Stock | |
| 25 mg | $143 | In Stock | |
| 50 mg | $239 | In Stock | |
| 100 mg | $355 | In Stock | |
| 200 mg | $527 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $61 | In Stock |
| Description | Icotinib Hydrochloride (BPI-2009H) is the hydrochloride salt form of icotinib, an orally available quinazoline-based inhibitor of EGFR, with potential antineoplastic activity. Icotinib selectively inhibits the wild-type and several mutated forms of EGFR tyrosine kinase. This may lead to an inhibition of EGFR-mediated signal transduction and may inhibit cancer cell proliferation. EGFR, a receptor tyrosine kinase, has been upregulated in a variety of cancer cell types. |
| Targets&IC50 | EGFR:5 nM |
| Synonyms | BPI-2009H |
| Molecular Weight | 427.88 |
| Formula | C22H22ClN3O4 |
| Cas No. | 1204313-51-8 |
| Smiles | Cl.C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1 |
| Relative Density. | no data available |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||
| Solubility Information | DMSO: 12 mg/mL (28.05 mM), Sonication is recommended. | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.